CLAIMS

1. Use of human stem cells or factors secreted therefrom in the preparation of a medicament for treating neuronal injury that is associated with axonal retraction, for reducing the adhesion of ED-1^+ cells to dystrophic axons that would result in axonal retraction, for reducing axonal retraction in a human subject, or for promoting axon regeneration in a subject, wherein the human stem cells are selected from the group consisting of embryonic stem cells and non-embryonic stem cells that have the ability to differentiate into cell types of more than one embryonic germ layer and/or express one or more of oct4, telomerase, rex- 1, rox-1, sox-2, and SSEA4.

2. The use of claim 1, wherein the stem cells have the ability to differentiate into cell types of more than one embryonic germ layer.

3. The use of claims 1-2, wherein the stem cells express telomerase.

4. The use of claims 1-3, wherein the stem cells express oct4.

5. The use of claims 1-4, wherein the stem cells are derived from bone marrow.

6. The use according to any of the above claims, wherein said medicament is for treating neuronal injury that is associated with axonal retraction.

7. The use according to any of the above claims, wherein said medicament is for reducing the adhesion of ED-1^+ cells to dystrophic axons that would result in axonal retraction.

8. The use according to any of the above claims, wherein said medicament is for reducing axonal retraction in a human subject.

9. The use of claim 7 wherein said ED-1^{+} cells are macrophages and/or microglia.

10. The use according to any of the above claims, wherein said medicament is for promoting axon regeneration in a human subject.

11. The use according to any of the above claims wherein the secreted factors are in cell culture medium conditioned by culturing the human stem cells therein.

12. The use according to any of the above claims wherein the neuronal injury is the result of spinal cord injury, brain injury, stroke, multiple sclerosis, epilepsy, or neuro-degenerative disease.

13. The use according to any of the above claims wherein the medicament comprising said secreted factors should be administered.

14. The use of claim 13 wherein said secreted factors are in medium conditioned by the human stem cells therein.